Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3

by Zacks Equity Research

Mylan's (MYL) Q3 revenues lag estimates due to persistent challenges in the North America segment.

Mylan (MYL) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 6.84% and -0.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

by Zacks Equity Research

We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up

by Zacks Equity Research

Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.

United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.

Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View

by Zacks Equity Research

Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.

Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?

by Zacks Equity Research

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.

Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View

by Zacks Equity Research

Amgen (AMGN) beats estimates for both earnings and sales in Q3 and raises guidance for the full year

Mylan (MYL) Q3 Earnings Preview: How Are Events Shaping Up?

by Zacks Equity Research

Mylan (MYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Amgen (AMGN) Keep the Earnings Streak Alive in Q3?

by Zacks Equity Research

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

Is a Beat in the Cards for Allergan (AGN) in Q3 Earnings?

by Zacks Equity Research

While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

Mallinckrodt (MNK) Gets $26 Million as Funding From BARDA

by Zacks Equity Research

Mallinckrodt (MNK) gets $26 million for additional funding from BARDA for pediatric studies of StrataGraft skin tissue in thermal burns.

AbbVie Settles With Novartis to Delay Humira Biosimilar in US

by Zacks Equity Research

AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

Generic-Drugs Stock Outlook: No Respite from Pricing Issues

by Zacks Equity Research

Generic drugmakers, in general, are having a rather poor year, primarily due to ongoing pricing pressure and rising competition.

    Ekta Bagri headshot

    Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead

    by Ekta Bagri

    Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.

      Glaxo's Tuberculosis Vaccine Positive in Mid-Stage Study

      by Zacks Equity Research

      Glaxo's (GSK) vaccine candidate, M72/AS01E, achieves significant reduction in incidence of pulmonary tuberculosis in HIV-negative patients with latent tuberculosis infection.

        Theravance Up as CHMP Backs Trelegy Elipta Line Extension

        by Zacks Equity Research

        Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.

          Mylan's Biosimilar of Neulasta Gets Positive CHMP Opinion

          by Zacks Equity Research

          Mylan (MYL) gets a positive CHMP opinion for Fulphila, a proposed biosimilar of Amgen's Neulasta.

            AbbVie Faces California Insurance Department Suit for Humira

            by Zacks Equity Research

            AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.

              Theravance, Mylan Report Positive Data on COPD Drug Yupelri

              by Zacks Equity Research

              Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.

                Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

                by Zacks Equity Research

                The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.

                  Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

                  by Zacks Equity Research

                  Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra

                    Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD

                    by Zacks Equity Research

                    FDA issues a complete response letter to Glaxo's (GSK) application for label expansion of its asthma drug, Nucala for COPD.

                      New Strong Sell Stocks for September 10th

                      by Zacks Equity Research

                      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                        Why Is Mylan (MYL) Up 6.3% Since Last Earnings Report?

                        by Zacks Equity Research

                        Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.